- Conditions
- NASH - Nonalcoholic Steatohepatitis, Fibrosis, Liver, NAFLD - Nonalcoholic Fatty Liver Disease
- Interventions
- CRV431 75mg, Placebo (1 softgel), CRV431 225mg, Placebo (3 softgels)
- Drug
- Lead sponsor
- Hepion Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 9
- States / cities
- Orange, California • Poway, California • Miami, Florida + 5 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 562
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Compensated Cirrhosis, Nonalcoholic Steatohepatitis
- Interventions
- aldafermin, Placebo
- Biological · Other
- Lead sponsor
- NGM Biopharmaceuticals, Inc
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 31
- States / cities
- Glendale, Arizona • Tucson, Arizona • North Little Rock, Arkansas + 22 more
- Conditions
- Non-alcoholic Fatty Liver Disease
- Interventions
- BI 1467335, Placebo
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 114 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 17
- States / cities
- Coronado, California • La Jolla, California • La Mesa, California + 13 more
- Conditions
- Non-Alcoholic Fatty Liver Disease, Liver Diseases, Liver Fat, Hepatic Steatosis, Nutritional and Metabolic Disease
- Interventions
- Whole Dairy
- Other
- Lead sponsor
- University of California, San Diego
- Other
- Eligibility
- 10 Years to 17 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- La Jolla, California
- Conditions
- NASH - Nonalcoholic Steatohepatitis, MASH - Metabolic Dysfunction-Associated Steatohepatitis
- Interventions
- Efruxifermin, Placebo
- Drug
- Lead sponsor
- Akero Therapeutics, Inc
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 2,150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 165
- States / cities
- Birmingham, Alabama • Dothan, Alabama • Chandler, Arizona + 139 more
- Conditions
- End Stage Liver Disease, NASH - Nonalcoholic Steatohepatitis, NAFLD - Nonalcoholic Fatty Liver Disease
- Interventions
- Tocotrienol (TCT), Placebo
- Drug · Other
- Lead sponsor
- Chandan Sen
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 110 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Non-alcoholic Fatty Liver Disease
- Interventions
- Efimosfermin Alfa, Placebo
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 1,250 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 57
- States / cities
- Arcadia, California • Covina, California • Los Angeles, California + 44 more
- Conditions
- Nonalcoholic Steatohepatitis, Nonalcoholic Fatty Liver Disease, Type 2 Diabetes Mellitus
- Interventions
- Pioglitazone study drug, Placebo, Pioglitazone Open Label
- Drug
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 176 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2014
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Nonalcoholic Steatohepatitis, Non-alcoholic Fatty Liver Disease
- Interventions
- IDN-6556, Placebo
- Drug · Other
- Lead sponsor
- Conatus Pharmaceuticals Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 7
- States / cities
- Miami, Florida • Indianapolis, Indiana • Detroit, Michigan + 4 more
- Conditions
- Non-alcoholic Steatohepatitis, Fatty Liver
- Interventions
- Omega 3 Fish Oil supplements, Placebo
- Drug
- Lead sponsor
- University of Virginia
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 1
- States / cities
- Charlottesville, Virginia
- Conditions
- NAFLD, MASLD
- Interventions
- E-trigger
- Behavioral
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Nonalcoholic Fatty Liver Disease (NAFLD), Type 2 Diabetes (T2DM)
- Interventions
- Lanifibranor, Placebo
- Drug · Other
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 21 Years to 75 Years
- Enrollment
- 128 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2023
- U.S. locations
- 1
- States / cities
- Gainesville, Florida
- Conditions
- NASH - Nonalcoholic Steatohepatitis
- Interventions
- Seladelpar, Placebos
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 181 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 14
- States / cities
- Glendale, Arizona • Tucson, Arizona • Los Angeles, California + 11 more
- Conditions
- Nonalcoholic Steatohepatitis
- Interventions
- GR-MD-02, Placebo
- Drug
- Lead sponsor
- Galectin Therapeutics Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Fort Sam Houston, Texas
- Conditions
- Non-alcoholic Steatohepatitis
- Interventions
- NNC0194 0499 50 mg/mL, Placebo (NNC0194-0499), Semaglutide 3 mg/mL, Semaglutide placebo, NNC0174 0833 10 mg/mL, NNC0174 0833 placebo
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- Not listed
- Enrollment
- 698 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 70
- States / cities
- Huntsville, Alabama • Chandler, Arizona • Peoria, Arizona + 59 more
- Conditions
- Non-Alcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis
- Interventions
- NRL972
- Drug
- Lead sponsor
- Norgine
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 125 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Familial Partial Lipodystrophy, Hypertriglyceridemia, Fatty Liver, NASH - Nonalcoholic Steatohepatitis
- Interventions
- 300mg Gemcabene, 600mg Gemcabene
- Drug
- Lead sponsor
- Elif Oral
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Non-Alcoholic Fatty Liver Disease (NAFLD), Non-Alcoholic Steatohepatitis (NASH), Liver Fibroses, Liver Steatoses
- Interventions
- Liver Incytes System
- Device
- Lead sponsor
- Sonic Incytes
- Industry
- Eligibility
- 19 Years to 75 Years
- Enrollment
- 164 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Liver Diseases, Liver Cirrhosis, NASH (Non-Alcoholic Steatohepatitis)
- Interventions
- Comprehensive Palliative Care services, Usual hepatic care
- Other
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Nonalcoholic Steatohepatitis, Nonalcoholic Fatty Liver
- Interventions
- OA-235i (4 mg), OA-235i (8 mg), OA-235i (16 mg), OA-235i (30 mg), OA-235i (40 mg), OA-235i or placebo
- Drug
- Lead sponsor
- Oasis Pharmaceuticals, LLC
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Nonalcoholic Steatohepatitis
- Interventions
- SEL, FIR, CILO, Placebo to match FIR, Placebo to match CILO, Placebo to match SEL
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 395 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 81
- States / cities
- Chandler, Arizona • Phoenix, Arizona • Little Rock, Arkansas + 62 more
- Conditions
- Metabolic Syndrome, Non-alcoholic Fatty Liver Disease, Obesity
- Interventions
- Low-fat diet, Low-carbohydrate diet
- Other
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 20 Years to 65 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2013
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Chronic Pancreatitis, Inflammatory Bowel Diseases, Hepatitis, NASH - Nonalcoholic Steatohepatitis, Acute Pancreatitis, Rheumatoid Arthritis, Diabetes Mellitus, Dyslipidemias, Multiple Sclerosis, Irritable Bowel Syndrome, Chronic Pain, Chronic Disease, Chronic Kidney Diseases, Crohn Disease, Celiac Disease, Biliary Cirrhosis, Bile Acid Synthesis Defect, Gastritis, Cholecystitis, Cholelithiases, IPMN, Cyst Pancreas, Cystic Fibrosis, Pancreatic Exocrine Insufficiency, Diarrhea Chronic, Constipation - Functional, Constipation Chronic Idiopathic
- Interventions
- venipuncture, Questionnaires, Additional Sample Collections
- Other · Behavioral
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- 12 Years and older
- Enrollment
- 120,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2026
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Nonalcoholic Steatohepatitis
- Interventions
- SEL, Placebo to match SEL 6 mg, Placebo to match SEL 18 mg
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 883 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 128
- States / cities
- Chandler, Arizona • Phoenix, Arizona • Little Rock, Arkansas + 93 more